HZNP Horizon Therapeutics Public Limited Company

35.87
-0.49  -1%
Previous Close 36.36
Open 36.42
Price To Book 4.32
Market Cap 6,718,530,954
Shares 187,302,229
Volume 774,765
Short Ratio
Av. Daily Volume 1,574,296
Stock charts supplied by TradingView

NewsSee all news

  1. Horizon Therapeutics Announces Significant Expansion and Relocation of U.S. Operations

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it has agreed to purchase the three-building campus in Deerfield that formerly belonged to Takeda Pharmaceuticals. The transaction is expected to close in the

  2. Horizon Therapeutics plc Announces Changes in Research and Development Organization

    - Scott Brun, M.D. Named Senior R&D Advisor - Horizon Therapeutics plc (NASDAQ:HZNP) today announced changes to its research and development organization structure. Effective immediately, Elizabeth H.Z. Thompson,

  3. The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease

    -- Phase 3 trial achieved its primary endpoint and all secondary endpoints with marked improvement in key indicators of disease -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that The New England Journal of

  4. FDA Approves TEPEZZATM (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)

    -- First and only FDA-approved medicine for TED, a serious, progressive, vision-threatening rare disease -- -- Clinical improvements were seen as early as six weeks, with continued improvement across the 24-week

  5. Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs

    -- Increases KRYSTEXXA® (pegloticase injection) Peak U.S. Annual Net Sales Expectations to More Than $1 Billion -- -- Increases Teprotumumab Peak U.S. Annual Net Sales Expectations to More Than $1 Billion -- --

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released December 8, 2016 - primary endpoint not met.
ACTIMMUNE
Friedreich's Ataxia (FA)
Phase 2 trial initiation announced September 27, 2018.
Krystexxa with Methotrexate
Gout
Randomized trial initiation announced June 20, 2019.
Krystexxa with Methotrexate - MIRROR RCT
Gout
FDA Approval announced January 21, 2020.
Teprotumumab
Thyroid Eye Disease (TED)

Latest News

  1. Horizon Therapeutics Announces Significant Expansion and Relocation of U.S. Operations

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it has agreed to purchase the three-building campus in Deerfield that formerly belonged to Takeda Pharmaceuticals. The transaction is expected to close in the

  2. Horizon Therapeutics plc Announces Changes in Research and Development Organization

    - Scott Brun, M.D. Named Senior R&D Advisor - Horizon Therapeutics plc (NASDAQ:HZNP) today announced changes to its research and development organization structure. Effective immediately, Elizabeth H.Z. Thompson,

  3. The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease

    -- Phase 3 trial achieved its primary endpoint and all secondary endpoints with marked improvement in key indicators of disease -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that The New England Journal of

  4. FDA Approves TEPEZZATM (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)

    -- First and only FDA-approved medicine for TED, a serious, progressive, vision-threatening rare disease -- -- Clinical improvements were seen as early as six weeks, with continued improvement across the 24-week

  5. Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs

    -- Increases KRYSTEXXA® (pegloticase injection) Peak U.S. Annual Net Sales Expectations to More Than $1 Billion -- -- Increases Teprotumumab Peak U.S. Annual Net Sales Expectations to More Than $1 Billion -- --

  6. MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate

    -- Seventy-Nine Percent of Patients Achieved a Complete Response -- -- New Data Continues to Support Immunomodulation Strategy to Improve Patient Outcomes -- Horizon Therapeutics plc (NASDAQ:HZNP) announced today

  7. FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)

    -- If approved, teprotumumab would be the first and only approved medicine for people living with TED, fulfilling a significant unmet need -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the Dermatologic

  8. Horizon Therapeutics plc Trading Halted Today; FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting to Discuss Teprotumumab for Thyroid Eye Disease

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that NASDAQ has halted trading of the Company's common stock. As per the U.S. Food and Drug Administration (FDA) guidelines for new molecular entities (NMEs), the

  9. Horizon Therapeutics plc to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the Company will participate in the 38th Annual J.P. Morgan Healthcare Conference. Timothy Walbert, chairman, president and chief executive officer will

  10. Horizon Therapeutics plc Opens New Manufacturing and R&D Facility in South San Francisco

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today the opening of its new office in South San Francisco, located at 2 Tower Place, 12th floor. The 20,000 square-foot facility will feature laboratory space that will

  11. Horizon Therapeutics plc Launches New Online Community Connecting People Living with Thyroid Eye Disease and Urging them to "Listen to Your Eyes"

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced the launch of "Listen to Your Eyes," a new website and Facebook community designed to provide education and support for people who are living with thyroid eye

  12. FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Workplaces for Parents List

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it has been named to FORTUNE Magazine's 2019 "Best Workplaces for Parents" list, which highlights companies that best support employees, regardless of

  13. Horizon Therapeutics plc to Participate in Upcoming Investor Conferences

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the Company will participate in the following upcoming conferences: Stifel 2019 Healthcare Conference Date: Tuesday, Nov. 19, 2019 Presentation Time:

  14. Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment Outcomes

    -- Horizon data at American College of Rheumatology Annual Meeting also cite the need for vigilance in treating gout among kidney transplant recipients -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced the

  15. The Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace

    Horizon Therapeutics plc (NASDAQ:HZNP) has been awarded a Top Workplaces 2019 honor by the Chicago Tribune. This is the fifth consecutive year Horizon has received this honor. "We take tremendous pride in being named

  16. Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019

    - Research, interactive features and charitable opportunity support advancement of care - Horizon Therapeutics plc (NASDAQ:HZNP) will join the leading voices in the nephrology community this week to inform and build

  17. Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced an integrated analysis of efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab will be presented during an oral session at the American

  18. New Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting

    -- Data to be presented from in-practice clinician case series on novel immunomodulation strategy -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced multiple presentations that will highlight the serious,

  19. Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced integrated, pooled efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab for the treatment of active thyroid eye disease (TED) compared to

  20. Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain's Chicago Business

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it is has been named one of the Most Innovative Companies in Chicago by Crain's Chicago Business, ranking number two. Crain's compiles the list based on a

  21. AVISE® MTX Test from Exagen Supports Horizon Therapeutics plc Clinical Trial to Evaluate Pegloticase with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout

    SAN DIEGO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), is pleased to announce clinical study support for Horizon Therapeutics plc (NASDAQ:HZNP) to measure methotrexate polyglutamates (MTXPGs), the

  22. New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid

  23. For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put "Vision First"

    -- Text the word "EYE" to 56512 to generate a donation from Horizon to Prevent Blindness to fund TED education -- Today, in support of World Sight Day, Horizon Therapeutics plc (NASDAQ:HZNP) and Prevent Blindness

  24. Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that its third-quarter 2019 financial results will be released on Wednesday, Nov. 6, 2019. Following the announcement, Horizon's management will host a live

  25. New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium

    Additional results from the Phase 3 confirmatory clinical trial (OPTIC) of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented at the American Society of Ophthalmic

  26. Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it has been named one of the top 100 adoption-friendly workplaces in the country by the Dave Thomas Foundation for Adoption, ranking number 56 overall and

  27. Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)

    -- If Approved, Teprotumumab Would be the First FDA-Approved Medicine for this Vision-Threatening Disease -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the U.S. Food and Drug Administration (FDA) has

  28. Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer

    - Current Executive Vice President and Chief Business Officer, Robert F. Carey, will Retire Effective Oct. 1. - DUBLIN – August 28, 2019 – Horizon Therapeutics plc (NASDAQ:HZNP) today named Andy Pasternak executive